Reversing Glucose and Lipid-mediated Vascular Dysfunction (REGAL)
Reversing Glucose and Lipid-mediated Vascular Dysfunction (REGAL)
Sponsor: University of Kansas Medical Center
Listed as NCT04832009, this EARLY_PHASE1 trial focuses on Blood Pressure and Hypertension and remains actively recruiting participants. Sponsored by University of Kansas Medical Center, it has been updated 9 times since 2022, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
9 versions recorded-
Jul 2025 — Present [monthly]
Recruiting EARLY_PHASE1
-
Nov 2024 — Jul 2025 [monthly]
Recruiting EARLY_PHASE1
Status: Unknown → Recruiting
-
Sep 2024 — Nov 2024 [monthly]
Unknown EARLY_PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Unknown EARLY_PHASE1
Status: Unknown Status → Unknown
-
Jun 2024 — Jul 2024 [monthly]
Unknown Status EARLY_PHASE1
Status: Recruiting → Unknown Status
▶ Show 4 earlier versions
-
Jun 2022 — Jun 2024 [monthly]
Recruiting EARLY_PHASE1
Status: Not Yet Recruiting → Recruiting
-
Oct 2021 — Jun 2022 [monthly]
Not Yet Recruiting EARLY_PHASE1
-
Sep 2021 — Oct 2021 [monthly]
Not Yet Recruiting EARLY_PHASE1
-
May 2021 — Sep 2021 [monthly]
Not Yet Recruiting EARLY_PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- University of Kansas Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .